Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed breast cancer * Metastatic disease * Must have received an aromatase inhibitor (e.g., letrozole, anastrozole, or exemestane) in an adjuvant or metastatic setting * If tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization) the patient must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen unless there is a contraindication to trastuzumab * Measurable or nonmeasurable disease, including any of the following : * Bone metastasis * Pleural/pericardial effusion * Ascites * Inflammatory skin changes * No microscopic residual disease only * Enrolled on or refused enrollment on clinical trial NCCTG-N0392 * No evidence of active brain metastasis including leptomeningeal involvement * CNS metastasis controlled (i.e., at least 2 months of no symptoms or evidence of progression) by prior surgery and/or raditherapy are allowed * Hormone receptor status: * Estrogen and/or progesterone receptor-positive tumor PATIENT CHARACTERISTICS: * Male or female * Female patients must be post-menopausal based on any 1 of the following criteria: * Age ≥ 60 years * Age ≥ 45 years with last menstrual period ≥ 12 months prior to study entry * Estradiol and follicle-stimulating hormone levels in postmenopausal range * History of bilateral oophorectomy * ECOG performance status 0-2 * Life expectancy \> 3 months * Fertile patients must use effective contraception during and for 30 days after completion of study treatment * WBC ≥ 3,000 mg/dL * Hemoglobin \> 8 g/dL * Absolute neutrophil count \> 1,000/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 times ULN * AST and ALT ≤ 2.5 times ULN * Creatinine ≤ 1.5 times ULN * Urine protein \< 1+ OR \< 1 g of protein by 24-hour urine collection * No nephrotic syndrome * No uncontrolled hypertension (i.e., blood pressure \[BP\] \> 160/90 mm Hg on ≥ 2 occasions at least 5 minutes apart) * Patients who have recently started or adjusted antihypertensive medications are eligible provided BP is \< 140/90 mm Hg on any new regimen for ≥ 3 different observations in ≥ 14 days * No clinically significant cardiac disease, including any of the following: * Congestive heart failure * Symptomatic coronary artery disease * Unstable angina * Cardiac arrhythmias not well controlled with medication * Myocardial infarction within the past 12 months * No arterial or venous thrombosis within the past 12 months * No hemoptysis or gastrointestinal hemorrhage within the past 6 months * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks * No significant traumatic injury within the past 4 weeks * No active, unresolved infection * No history of hypertensive crisis or hypertensive encephalopathy * No history of bleeding diathesis or uncontrolled coagulopathy * No history of cerebrovascular accident, hemorrhage, or stroke * No allergy or hypersensitivity to drug product excipients, murine antibodies, or agents chemically similar to study drugs * No other malignancy within the past 3 years except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * No other serious medical condition that would preclude study therapy or compliance PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior radiotherapy to a target lesion allowed provided there has been clear progression since radiotherapy was completed * At least 4 weeks since prior radiotherapy * Single-dose radiation for palliation or to a nontarget lesion only allowed within the past 4 weeks * No more than 1 prior chemotherapy regimen for metastatic disease * No more than 2 prior endocrine (hormonal) therapy regimens in the neoadjuvant, adjuvant, or metastatic setting * At least 4 weeks since prior major surgery or open biopsy * At least 4 weeks since prior chemotherapy or immunologic therapy * At least 2 weeks since prior and no concurrent use of any of the following agents: * Aspirin (daily low-dose \[81 mg\] aspirin allowed\]) * Thrombolytic agents * Anticoagulants (low-dose anticoagulation therapy to maintain patency of a vascular access device is allowed) * No concurrent treatment in another clinical study with investigational procedures or investigational therapies * No other concurrent anticancer therapy, including chemotherapy, biologic agents, or radiotherapy * No routine use of granulocyte colony-stimulating factors during course 1 * No concurrent oprelvekin